The angiogenesis inhibitor vasostatin is regulated by neutrophil elastase–dependent cleavage of calreticulin in AML patients by Sarah Mans, Yara Banz,

Slides:

Advertisements

Similar presentations

Increased peripheral platelet destruction and caspase-3– independent programmed cell death of bone marrow megakaryocytes in myelodysplastic patients by.

Advertisements

Stem cell concepts renew cancer research by John E. Dick Blood Volume 112(13): December 15, 2008 ©2008 by American Society of Hematology.

Extracellular matrix protein tenascin-C is required in the bone marrow microenvironment primed for hematopoietic regeneration by Ayako Nakamura-Ishizu,

Platelet activation and inhibition in polycythemia vera and essential thrombocythemia by Carlo Patrono, Bianca Rocca, and Valerio De Stefano Blood Volume.

1A 1B 1C 1D Supplementary Fig. 1. Treatment of VEGF-C with the human acute myeloid leukemic cell line,THP-1, induced angiogenesis in vitro. (A and B) Treatment.

Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients by Mikkael A. Sekeres, Paul Elson,

Phenotypic and Functional Changes Induced at the Clonal Level in Hematopoietic Stem Cells After 5-Fluorouracil Treatment by Troy D. Randall, and Irving.

Dendritic cells accumulate in the bone marrow of myeloma patients where they protect tumor plasma cells from CD8 + T-cell killing by Patrizia Leone, Simona.

SK053 An Inhibitor Of Enzymes Involved In Allosteric Disulfide Bonds Formation Induces Differentiation Of Human AML Cells by Justyna Chlebowska, Malgorzata.

The Prognostic Value Of Dynamic Monitoring C-Reactive Protein (CRP) Serum Levels In NK/T-Cell Lymphoma by Bing Bai, Qi-chun Cai, Xiao-Xiao Wang, Qingqing.

Comparison of Unmobilized and Mobilized Graft Characteristics and the Implications of Cell Subsets on Autologous and Allogeneic Transplantation Outcomes

Immunologic effects of F16-IL2 therapy.

CBFB-SMMHC is correlated with increased calreticulin expression and suppresses the granulocytic differentiation factor CEBPA in AML with inv(16)‏ by Daniel.

by Benjamin J. Frisch, John M. Ashton, Lianping Xing, Michael W

by Venetia Bigley, Laura E. Spence, and Matthew Collin

Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients by Mikkael A. Sekeres, Paul Elson,

In utero transplantation may soon be in delivery

How I treat hairy cell leukemia

ATRA resolves the differentiation block in t(15;17) acute myeloid leukemia by restoring PU.1 expression by Beatrice U. Mueller, Thomas Pabst, José Fos,

by Zhenping Zhu Blood Volume 108(6): September 15, 2006

Acute myeloid leukemia creates an arginase-dependent immunosuppressive microenvironment by Francis Mussai, Carmela De Santo, Issa Abu-Dayyeh, Sarah Booth,

How I treat elderly patients with myeloma

Deficient CEBPA DNA binding function in normal karyotype AML patients is associated with favorable prognosis by José Fos, Thomas Pabst, Vibor Petkovic,

Mechanisms of HIV-associated lymphocyte apoptosis

Tumor cell agglutination and not solely cytokine release as mechanism of adverse reactions during anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab)

Leukemia initiated by PMLRARα: the PML domain plays a critical role while retinoic acid–mediated transactivation is dispensable by Scott C. Kogan, Suk-hyun.

Skovseth et al. Endostatin dramatically inhibits endothelial cell migration, vascular morphogenesis, and perivascular cell recruitment in vivo. Blood.

by Petri Salven, Lasse Teerenhovi, and Heikki Joensuu

SOX11 holds mantle cell lymphoma’s key to home

Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia by Teresa Padró, Sandra Ruiz, Ralf Bieker, Horst Bürger, Martin Steins,

Functional neutrophils from human ES cells

A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia by Gerald G. Wulf, Rui-Yu Wang, Ingrid Kuehnle, Douglas Weidner, Frank.

Bone morphogenetic protein 4 induces efficient hematopoietic differentiation of rhesus monkey embryonic stem cells in vitro by Fei Li, Shijiang Lu, Loyda.

Increased Phagocyte FcγRI Expression and Improved Fcγ-Receptor–Mediated Phagocytosis After In Vivo Recombinant Human Interferon-γ Treatment of Normal Human.

by Alexander Röth, Andreas Hüttmann, Russell P

by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle

Selective Ablation of Acute Myeloid Leukemia Using Antibody-Targeted Chemotherapy: A Phase I Study of an Anti-CD33 Calicheamicin Immunoconjugate by E.L.

Enhancement of the host immune responses in cutaneous T-cell lymphoma by CpG oligodeoxynucleotides and IL-15 by Maria Wysocka, Bernice M. Benoit, Sarah.

by Giridharan Ramsingh, Meagan A. Jacoby, Jin Shao, Rigoberto E

Lymphoma spread? Target CD47-SIRPα!

Gene expression and immunologic consequence of SPAN-Xb in myeloma and other hematologic malignancies by Zhiqing Wang, Yana Zhang, Haichao Liu, Emanuela.

The multidrug resistance-associated protein 3 (MRP3) is associated with a poor outcome in childhood ALL and may account for the worse prognosis in male.

A Strong Expression of CD44-6v Correlates With Shorter Survival of Patients With Acute Myeloid Leukemia by S. Legras, U. Günthert, R. Stauder, F. Curt,

Yang et al. SALL4 is a key regulator of survival and apoptosis in human leukemic cells. Blood. 2008;112(3):805–813. Blood Volume 114(14): October.

Complete remission through blast cell differentiation inPLZF/RARα-positive acute promyelocytic leukemia: in vitro and in vivo studies by Maria C. Petti,

Up-Regulation of α4β7 Integrin on Peripheral T Cell Subsets Correlates with the Development of Acute Intestinal Graft-versus-Host Disease following Allogeneic.

Small-molecule XIAP inhibitors derepress downstream effector caspases and induce apoptosis of acute myeloid leukemia cells by Bing Z. Carter, Marcela Gronda,

Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal.

by Geling Li, Emily Waite, and Julie Wolfson

Kruppel-like factor 4 regulates neutrophil activation

Systemic inflammation induces release of cell-free DNA from hematopoietic and parenchymal cells in mice and humans by Anne Jan van der Meer, Anna Kroeze,

A phase 1 trial evaluating thioridazine in combination with cytarabine in patients with acute myeloid leukemia by Lili Aslostovar, Allison L. Boyd, Mohammed.

HOXB6 overexpression results in delayed AML

Hematopoietic potential of HEP from patient-specific iPSC may be reduced. Hematopoietic potential of HEP from patient-specific iPSC may be reduced. (A)

Health outcomes and services in children with sickle cell trait, sickle cell anemia, and normal hemoglobin by Sarah L. Reeves, Hannah K. Jary, Jennifer.

A case of lenalidomide-dependent myelodysplastic syndrome

A and B: Flow cytometric analysis of the effect of MRP-8/14 in the serum of a type 1 diabetic patient on the surface expression of CD11b and CD118. A and.

Treatment versus Transplant for Challenging Hematologic Disorders

Erratum in Ledru et al. Alteration of tumor necrosis factor–α T-cell homeostasis following potent antiretroviral therapy: contribution to the development.

Resistance mechanism for ibrutinib in marginal zone lymphoma

Leukemic blasts express a “hypoxia signature

Representative staining of bone marrow aspirates collected from a patient at baseline and after 1 cycle of treatment with 45 mg/m2 selinexor + 20 mg dexamethasone,

Pure red cell aplasia by Robert T. Means Blood

SY-1425 induces maturation in RARA-high AML

Bortezomib induces an NRF2 signature and NRF2 protein in tumor cells from leukemic MCL. Gene sets regulated by bortezomib (Supplementary Tables S3 and.

Myeloproliferative neoplasms and thrombosis

by Chatree Chai-Adisaksopha, Davide Matino, and Alfonso Iorio

How to establish the diagnosis of LGL leukemia.

Bone marrow fibrosis associated with long-term imatinib therapy: resolution after switching to a second-generation TKI by Naranie Shanmuganathan, Susan.

by Wolfgang Warsch, Christoph Walz, and Veronika Sexl

Presentation transcript:

The angiogenesis inhibitor vasostatin is regulated by neutrophil elastase–dependent cleavage of calreticulin in AML patients by Sarah Mans, Yara Banz, Beatrice U. Mueller, and Thomas Pabst Blood Volume 120(13): September 27, 2012 ©2012 by American Society of Hematology

Anthracyclin treatment induces CRT expression on the cell surface and in the serum. Sarah Mans et al. Blood 2012;120: ©2012 by American Society of Hematology

Calreticulin surface expression (cs-CRT) and extracellular serum CRT levels in patients with AML. (A) Leukemic cells from patients with AML at diagnosis and myeloid cells from 75 healthy volunteers were CD45+ gated and CD33+/CRT+ cells were determined. Sarah Mans et al. Blood 2012;120: ©2012 by American Society of Hematology

NE releases N-terminus CRT in patients with AML. (A) Recombinant full-length CRT protein was digested by NE at pH 6.0 and pH 7.4 for 2 hours. Sarah Mans et al. Blood 2012;120: ©2012 by American Society of Hematology

Vasostatin impairs differentiation. Sarah Mans et al. Blood 2012;120: ©2012 by American Society of Hematology

Vasostatin levels inversely correlate with MVD in patients with AML. Immunohistochemical staining of bone marrow biopsies with von VWF identifying endothelial vessel structures (stained brown). Sarah Mans et al. Blood 2012;120: ©2012 by American Society of Hematology

Patients with increased vasostatin levels have a favorable outcome. Sarah Mans et al. Blood 2012;120: ©2012 by American Society of Hematology